RNA · ISSUER CIK 2093101
Atrium Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 8 Atrium Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $0.00 of sales on SEC Form 4.
↗8 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$0.00Insider buying
$0.00Insider selling
$0.00Net open-market
Sep 22, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 22, 202616:24 | Sep 18, 2026 | RNA | Chief Scientific Officer | F · Tax | $8.95 | −11,216 | 41,441 | -21% | $100K | ||
| Sep 22, 202616:23 | Sep 18, 2026 | RNA | Chief Medical Officer | F · Tax | $8.95 | −21,459 | 51,638 | -29% | $192K | ||
| Sep 22, 202616:20 | Sep 18, 2026 | RNA | Director | F · Tax | $8.95 | −22,812 | 31,974 | -42% | $204K | ||
| Sep 22, 202616:20 | Sep 18, 2026 | RNA | Director | F · Tax | $8.95 | −126,418 | 138,668 | -48% | $1.1M | ||
| Sep 22, 202616:18 | Sep 18, 2026 | RNA | See Remarks | F · Tax | $8.95 | −2,375 | 33,085 | -7% | $21K | ||
| Sep 22, 202616:17 | Sep 18, 2026 | RNA | See Remarks, Director | F · Tax | $8.95 | −11,632 | 119,729 | -9% | $104K | ||
| Sep 22, 202616:17 | Sep 18, 2026 | RNA | Chief Financial Officer | F · Tax | $8.95 | −6,742 | 36,859 | -15% | $60K | ||
| Sep 22, 202616:15 | Sep 18, 2026 | RNA | Chief Strategy Officer | F · Tax | $8.95 | −8,320 | 38,340 | -18% | $74K |